There is increasing evidence that T cells have potent innate anti-tumor activity. We described previously that synthetic aminobisphosphonates are potent T cell stimulatory compounds which induce cytokine secretion (i. e. IFN-) and cell- 
Introduction
Despite significant improvement in the treatment of low-grade NHL and MM, the vast majority of patients relapses or becomes resistant to conventional treatment strategies such as chemotherapy or radiation. Therefore, there is need for alternative tumor therapies. One possibility is manipulating the immune system to target and eliminate neoplastic cells. The aim of this pilot study is to evaluate the feasibility of activation and/or expansion of T cells in vivo using the combination of pamidronate and IL-2 in patients with refractory/relapsed lymphoma or myeloma, to determine the most effective IL-2 dose, to assess the toxicity of this regimen, and to evaluate its ability to exert anti-tumor effects.
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Patients, materials, and methods

Patients
Adults suffering from low-grade B-cell lymphoma (NHL) or multiple myeloma (MM), refractory or relapsing after salvage therapy were entered on the protocol. All patients signed an informed consent according to guidelines of the local ethics committee.
Eligibility criteria required (1) an ECOG score of less than three, and (2) no severe impairment of cardiac, renal or hepatic function. Pretreatment evaluation and follow up studies included a history and physical examination, complete blood counts, extensive immunological monitoring by FACS analysis of peripheral blood lymphocytes, CT scans, ultrasound, PET scans, or bone marrow biopsy which ever appropriate.
Response criteria
Complete remission required disappearance of all lymphoma manifestations for at least four weeks. Partial remission was defined as 50% reduction or more of all measurable lymphoma manifestations for at least four weeks. In addition, no single manifestation should have shown enlargement of 25% or more in size and no new lesions should have appeared during that period. Stable disease meant less than 50% reduction or no measurable change in lymphoma manifestations. Progressive disease (PD) was defined as increase of frequency and severity of disease associated symptoms and/or occurrence of new nodal or extra nodal lesions and/or increase of preexisting lymphoma manifestations by more than 25%.
Adverse events were assessed according to WHO criteria.
T cell proliferation assay
T cell proliferation assay was described previously 8 . Briefly, 5x10 4 PBMC were cultivated in triplicate in 100 µl RPMI 1640 medium per well (Gibco, NY, USA), 10%
pooled human AB serum, and 100 IU/ml IL-2 in round-bottom microtiter plates (Nunc, Wiesbaden, Germany). ( T cell number in pamidronate/IL-2 culture) -( T cell number in medium/IL-2) / ( T cell number in medium/IL-2) x 100. A stimulation index > 2 was considered as significant increase of T cells. More than 5% of T cells in PBMC culture on day 7 were required to avoid non-proportional increases at lower numbers.
FACS analysis of peripheral blood
Blood samples of patients were collected before each treatment course and on days 2 or 3, and 7 after start of treatment. PBMC were stained with FITC, PE or APC 
Results
Nineteen patients, with a median age of 61 (range, 36-83 years) were enrolled in this pilot study (Table 1A and 1B) . 11 patients (58%) had a diagnosis of low -grade B-NHL (4 FCL, 4 CLL, 2 MZL, 1 IC) and 8 patients of MM (42%). The majority of patients had advanced disease and received pamidronate/IL-2 as their second or subsequent salvage therapy (74%). Only patients with progressive disease were eligible for inclusion in the study.
Treatment schedule
The treatment schedule was adopted from our in vitro experience, where up to 50-fold expansion of T cells was achieved in the presence of pamidronate and IL-2.
The consequences of a selective activation of T cells in vivo were not known at the beginning of the study and pamidronate alone could have induced a cytokinemediated acute phase reaction. Therefore, the first 10 patients (cohort A, Table 1A) received increasing dose levels of continuous 24-hour IV infusions of low dose IL-2 
Activation and proliferation of T cells
None of the first 10 patients (cohort A, patients 1A-10A) showed a measurable T cell response during pamidronate/IL-2 treatment in vivo, even at the highest IL-2 dose level (Table 1A) . Although in vitro proliferation of T cells in response to pamidronate/IL-2 was not regularly examined in this patient group, the majority of tested patients (4 out of 5) had negative in vitro proliferation assays (Table 1A) .
Therefore, in vitro testing of T cells in response to pamidronate/IL-2 was performed for all further eligible patients and only patients with significant in vitro proliferation qualified for study entry. Compared with an age-matched group of healthy donors where 88% exhibited an in vitro response to pamidronate/IL-2, only 49% of patients with lymphoid malignancies (n=41) showed significant in vitro T cell proliferation (Table 2 ). In accordance with the data observed in vivo, the proportion of patients with B-CLL showing T cell proliferation to pamidronate/IL-2 in vitro was quite low.
Thus, the underlying disease (e.g. B-CLL) seems to have an impact on T cell reactivity. Furthermore, in vitro testing revealed that addition of IL-2 on day 1 instead of day 3 significantly increased proliferation of T cells in response to pamidronate (data not shown).
Based on these results, we changed the treatment schedule (IL-2 start on day 1) and only patients with significant in vitro proliferation of T cells to pamidronate/IL-2 were defined to be eligible. In this patient group (cohort B, patients 1B -9B) significant in vivo proliferation of T cells could be achieved in 5 out of 9 patients (55%) ( Table   1B ). The pronounced effect of the pamidronate/IL-2 combination on T lymphocytes in vivo becomes even more evident when expression of activation markers was analyzed (Table 3A) . In contrast to T cells and NK cells, we found a significant increase of CD69 and/or HLA-DR activation antigens on T cells. Concomitant expression of early (CD69) and late (HLA-DR) activation markers demonstrates a more specific stimulation. Both antigens were up-regulated on T cells in a dose dependent manner, while on T cells and NK cells, this effect was achieved only at the highest dose level of IL-2 in a significant proportion of patients (Table 3A) .
In addition, significant expansion of V 9 2 T cells, which are the target population of pamidronate stimulation, was observed in vivo (Table 3B) 
Clinical response to therapy
None of the 9 analyzable patients of cohort A (patients 1A -10A) achieved an objective tumor response (Table 1A) . In one patient (patient 2A) stable disease was observed which lasted 6 months.
In contrast, 3 out of 9 patients in cohort B (patients 5B, 8B, 9B) achieved a partial remission (PR) giving an objective response rate of 33% (Table 1B) . Two additional patients achieved stable disease, still ongoing after 7 months (patient 7B) and lasting Thereafter, tumor mass steadily declined and after 19 months of treatment, a PR has been reached (Fig. 3) .
Patient 8B had relapsed with a follicle center lymphoma and developed multiple subcutaneous manifestations in addition to multiple lymph node involvement. After start of pamidronate/IL-2 treatment, the subcutaneous nodules rapidly disappeared (Fig. 3) , whereas nodal manifestations regressed slowly. Two months later, treatment was stopped due to incompliance of the patient.
Patient 5B suffered from an IgA multiple myeloma (stage IIA) refractory to conventional chemotherapy. After 9 cycles of immunotherapy his bone marrow was cleared from tumor cells and IgA level decreased from 3400 mg/dl to 1740 mg/dl. Table 1B ).
After these modifications, significant in vivo expansion of T cells could be observed in 5 out of 9 patients (55%) ( Table 1B) . In vivo proliferation of T cells was associated with a robust up-regulation of early (CD69) and late (HLA -DR) activation markers, while pamidronate and IL-2 failed to induce comparable effects on T cells and NK cells (Table 3A) . These data support in vitro findings that the action of Another aim of our study was to assess the clinical response. None of the 9 analyzable patients of cohort A (Table 1A) achieved an objective tumor response.
After change of protocol and inclusion criteria (cohort B, Table 1B X no absolute counts available, however percentage of T cells increased from 7% to 19.5%. n.d., not done. f Response: SD, stable disease; PR, partial remission; PD, progressive disease. n.e., not evaluable. -rituximab, Dexa-BEAM, dexamethasone/carmustine/etoposide/cytarabine/melphalan;TBI/CY, total body irradiation/ high dose cyclophosphamide followed by PBSCT; LR, local radiotherapy (dose); HD-M, high dose melphalan followed by PBSCT; TNI, total nodal irradiation (dose); IFN, interferon-(maintenance therapy). c Months between last chemotherapy/radiotherapy and first pamidronate/IL-2 treatment. d Side effects: T, Thrombophlebitis; F, Fever; S, Skin-erythema; I, Infection; (2) WHO grade 2. e T cell proliferation: In vitro: results represent percentage of control culture according to the following calculation: ( T cell number in pamidronate/IL-2 culture) -( T cell number in medium/IL-2) / ( T cell number in medium/IL-2) x 100. In vivo: results represent % increase according to the following calculation: (V 9 2 T cell number on day 8 after pamidronate/IL-2 infusion) -(V 9 2 T cell number before treatment) / (V 9 2 T cell number before treatment) x 100. -= <20%; + = 20% -100%; ++ = >100% -200%; +++ = >200% increase of T cell number.
X no absolute counts available, however percentage of T cells increased from 7% to 19.5%. n.d., not done. Cytokine concentrations were determined in serum using ELISA systems. CT scans of patient 8B and 9B before and after several cycles of pamidronate/IL-2 therapy show regression of skin metastases and mediastinal lymph node (arrows), respectively.
